Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
194
resultados
Última actualización
09/08/2025 [06:55:00]
Resumen de: US2025248937A1
The invention provides novel compositions of fluorocarbon nanoemulsions comprising one or more of fluorosurfactants and phospholipids, and methods of preparation and use thereof for enhanced oxygen delivery.
Resumen de: US2025250227A1
The present disclosure relates to an amino lipid compound, a preparation method therefor, a composition thereof and the use thereof. Specifically, the present disclosure relates to an amino lipid compound represented by formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof, and the use thereof in the formulation of a lipid nanoparticle for delivering an active ingredient. The present disclosure also relates to a composition containing the amino lipid compound, and in particular relates to a lipid nanoparticle and the use thereof.
Resumen de: US2025249123A1
Provided herein are lipids having the Formula I or Formula Ia:and pharmaceutically acceptable salts thereof, wherein R′, R1, R2, R3, R4, R5, R6a, R6b, X1, X2, and n are as defined herein for Formula I and Formula Ia, respectively. Also provided herein are lipid nanoparticle (LNP) compositions comprising lipid having the Formula I or Ia and a capsid-free, non-viral vector (e.g., ceDNA). In one aspect of any of the aspects or embodiments herein, these LNPs can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like).
Resumen de: US2025249122A1
The subject matter disclosed herein is directed to nitric oxide releasing particles comprising a mesoporous silica network. Also disclosed are compositions comprising one or more nitric-oxide releasing particles and a polymer. In one aspect, the particles are admixed with the polymer. The compositions exhibit high payloads of nitric oxide release without particle leaching or the need for extremely cold storage conditions.
Resumen de: US2025249059A1
Disclosed herein are a non-bee made honey formulations comprising fructose in an amount from about 20% to about 55% w/w; glucose in an amount from about 20% to about 40% w/w; one or organic acids in an amount from about 0.001% to about 5% w/w; water; and one of the following: one or more polyphenols in a concentration of at least 0.4 mM; or a total antioxidant capacity of at least 1,500 nM/uL Trolox Equivalents. In some embodiments, the total antioxidant capacity is at least that of natural bee-made clover honey. In some embodiments, the total antioxidant capacity exceeds that of natural bee-made clover honey.
Resumen de: US2025249062A1
Provided is a use of dipsaci radix-derived extracellular vesicle-like nanoparticles (DREVNs) in preparation of a drug for preventing or treating orthopedic diseases. In this application, EVs are creatively extracted from dipsaci radix and purified, and the physiological efficacy of the EVs is studied. It has been found that the EVs can be fully internalized by bone marrow mesenchymal stem cells (BMSCs), can promote the osteogenic differentiation of BMSCs by activating a BMP2/Smads signaling pathway, promote the calcified nodule formation in BMSCs, and promote the expression of osteogenic differentiation-associated genes ALP, OCN, RUNX2, and COL1, and have bone targetability in vivo. The EVs can be intragastrically administered to alleviate the osteoporosis (OP) in postmenopausal mice. Therefore, the EVs have the potential of being used to prepare drugs for preventing or treating orthopedic diseases, and provide a new strategy for the prevention or treatment of orthopedic diseases.
Resumen de: US2025248926A1
Prolonged delivery of chemodrugs locally inside the brain with sufficient tissue-penetration is a critical requirement for treating various brain-diseases including malignant tumors. The present disclosure relates to an injectable microparticle system for brain-drug delivery. The injectable microparticle system comprising drug-loaded polymeric microparticles, wherein the drug-loaded polymeric microparticles are coated with an outer polymer gel layer enabling in-situ formation and releasing drug-polymer nanocomplexes of size <100 nm. The injectable microparticle system facilitates both deep tissue penetration for >2 cm as well as ‘sustained release’ of the drug for 15-30 days. The invention also discloses a method of producing said injectable microparticle system and the use of said injectable microparticle system in the treatment of brain tumor and other cancers.
Resumen de: US2025248939A1
Provided herein are, inter alia, nucleic acids, lipid nanoparticles, lipid nanoparticles comprising nucleic acids encapsulated therein, pharmaceutical compositions comprising lipid nanoparticles which comprise nucleic acids encapsulated therein, methods of treating diseases, such as cancer, and methods of delivering lipid nanoparticles to myeloid cells, lymphoid organs, and tumors.
Resumen de: US2025248946A1
Methods and compositions for cellular rejuvenation of immune cells, such as T cells, are provided. Cellular rejuvenation can be achieved by exposure, such as transient exposure, of immune cells to mRNAs encoding reprogramming factors. Compositions comprising such rejuvenated immune cells, including rejuvenated T cells, and uses of the rejuvenated immune cells in treating certain diseases and/or disorders, such as cancer and immune disorders, are also provided
Resumen de: US2025248986A1
The present disclosure provides an antifungal drug inhalation formulation, comprising: crystalline nanoparticles of a triazole antifungal drug. The present disclosure further provides a preparation method and use of the antifungal drug inhalation formulation.
Resumen de: US2025248928A1
Nanoparticles and nanoparticle-releasing vaginal rings for intermediate- to long-term delivery of drugs to the female genital and reproductive tract have been developed. The nanoparticles are loaded with drugs and coated with a sheddable poly(ethylene glycol) (PEG) layer that promotes mucus penetration and then converts to an adhesive form after penetration. This platform technology readily distributes drug through the mucosa and throughout the vaginal tissue, enhances local retention of drugs within the vaginal tissue, thereby providing a sustained delivery of drugs beyond the natural shedding and turnover of vaginal mucous and epithelial cells.
Resumen de: US2025248978A1
The present invention provides methods and compositions for treating epithelioid cell tumors (such as a PEComa) by administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin.
Resumen de: US2025248997A1
The present invention relates to methods of treating schizophrenia using a combination of aripiprazole, aripiprazole lauroxil, and a nanoparticle dispersion of aripiprazole lauroxil.
Resumen de: US2025249099A1
Compositions and methods for making and using engineered NK cells, T cells and B cells that express a chimeric antigen receptor.
Resumen de: AU2023408649A1
The present invention provides, in part, bis-ester and amide cationic lipid compounds of Formula (I):, or a pharmaceutically acceptable salt thereof, bis-ester and amide cationic lipid compounds of Formula (II):, or a pharmaceutically acceptable salt thereof, bis-ester and amide cationic lipid compounds of Formula (III):, or a pharmaceutically acceptable salt thereof, and bis-ester and amide cationic lipid compounds of Formula (IV):, or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.
Resumen de: AU2023408533A1
The present invention relates to a process of preparing stable nanoparticles and pharmaceutical composition thereof. Moreover, the nanoparticles prepared from the process are with a stable and controlled mean particle size and particle size distribution.
Resumen de: AU2024212425A1
Disclosed herein are modified lipid compositions comprising (a) a structural component comprising one or more lipids selected from the group consisting of soy-derived lipids, cardiolipin, sphingolipid, ceramide, glucosyl ceramide, lactosyl ceramide, galactosyl cholesterol, glucosyl cholesterol; and modified by (b) an ionizable lipid. The disclosure also includes a method for making a modified lipid composition, comprising reconstructing (a) a structural component comprising one or more lipids selected from the group consisting of soy-derived lipids, cardiolipin, sphingolipid, ceramide, glucosyl ceramide, lactosyl ceramide, galactosyl cholesterol, and/or glucosyl cholesterol in the presence of (b) an ionizable lipid, to produce the modified lipid composition, and loading into the modified lipid composition with one or more heterologous functional agents.
Resumen de: AU2024245504A1
The present invention relates to a method for synthesizing nanoparticles consisting of or comprising at least one zeolite nanocrystal according to which: - a first composition/solution 1 containing an aluminum source and a source of an ion of an alkali metal M, in particular Na, is prepared; a second composition/solution 2 comprising a silicon source and a source of an ion of an alkali metal M, in particular Na, is prepared, said solutions 1 and 2 being free of any organic structuring agent; - the two compositions/solutions 1 and 2 are mixed; - the mixture is crystallized; and - said nanoparticles thus formed are optionally separated. According to the invention, said first composition/solution 1 and said second composition/solution 2 are both constituted of said source and of an alkaline phosphate buffer (PBS). The present invention also relates to the nanoparticles obtained and compositions containing them.
Resumen de: AU2025205468A1
The present invention provides, among other things, methods and compositions of formulating nucleic acid-containing nanoparticles for efficient delivery of payload in vivo such that the method and compositions can be used to generate mRNA vaccines. The present invention provides, among other things, methods and compositions of formulating nucleic acid-containing nanoparticles for efficient delivery of payload in vivo such that the method and compositions can be used to generate mRNA vaccines. ul h e p r e s e n t i n v e n t i o n p r o v i d e s , a m o n g o t h e r t h i n g s , m e t h o d s a n d c o m p o s i t i o n s o f u l f o r m u l a t i n g n u c l e i c a c i d - c o n t a i n i n g n a n o p a r t i c l e s f o r e f f i c i e n t d e l i v e r y o f p a y l o a d i n v i v o s u c h t h a t t h e m e t h o d a n d c o m p o s i t i o n s c a n b e u s e d t o g e n e r a t e m v a c c i n e s
Resumen de: US2025251396A1
Bead constructs of sizes in the nanometer to micrometer range with a primary functionalization of a lipid membrane with embedded anchor peptides are provided. The anchor peptides may be adapted for a secondary functionalization of active molecules that are bound to the anchor peptides by transpeptidation or similar process. The functionalized bead platform can be adaptable and used in many different applications including biochemical and cellular assays, molecular diagnostics such as protein-protein interactions, protein-DNA interactions, DNA detection, separations, purifications, imaging, and microfluidics.
Resumen de: US2025250226A1
Ionizable compounds, and compositions and methods of use thereof. The ionizable compounds can be used for making nanoparticle compositions for use in biopharmaceuticals and therapeutics. More particularly, the compounds, compositions and methods are to provide nanoparticles to encapsulate active agents, such as nucleic acid agents, and to deliver and distribute the active agents to cells, tissues, organs, and subjects.
Resumen de: US2025250576A1
In some aspects, the invention provides a method of treating atherosclerosis in a subject. The method comprises administering to the subject an agent that increases the activity or level of a let-7 miRNA or an agent that decreases activity or level of a TGFβ signaling polypeptide in an endothelial cell in the subject. In some embodiments, the subject is administered an additional agent comprising a therapeutically effective amount of rapamycin or any derivative thereof. In some embodiments, the agent is a let-7 miRNA. In some other aspects, the invention provides a pharmaceutical composition comprising a let-7 miRNA. In some embodiments, the let-7 miRNA is encapsulated in a nanoparticle formulated for selective delivery to an endothelial cell.
Resumen de: US2025248945A1
The disclosure relates, in part, to biodegradable lipid nanoparticles (LNPs) comprising biodegradable lipidoid compounds and compositions thereof. In certain embodiments, the LNPs selectively target a cell of interest (e.g., an immune cell, stem cell, bone cell, blood cell, fat cell, endothelial cell, cancer cell, tissue cell, nerve cell, epithelial cell, connective tissue cell, and muscle cell, inter alia). In certain embodiments, the disclosure further relates to methods for in vivo delivery of therapeutic agents for the treatment, prevention, and/or amelioration of diseases or disorders using the LNPs of the disclosure.
Resumen de: US2024150306A1
Provided herein are compounds having one or more cleavable disulfide moieties and one or more hydrophobic tail moieties (HTM) for delivery of one or more therapeutic or diagnostic agents. In some embodiments, the one or more therapeutic or diagnostic agents are biologics. In some embodiments, the one or more therapeutic or diagnostic agents are delivered to cancer cells.
Nº publicación: EP4594743A1 06/08/2025
Solicitante:
MERCK SHARP & DOHME LLC [US]
Merck Sharp & Dohme LLC
Resumen de: WO2024072929A1
The present disclosure provides a method of assessing translation efficacy of an mRNA using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The mRNA is first translated into protein either in a cell lysate (cell-free translation; CFT) or inside a cell (cell-based translation; CBT) and analyzed using LC-MS/MS. The method provides advantages such as speed and convenience over traditional immunoassay-based methods of detecting translated proteins. Translation using CBT may be necessary in certain formulations of the mRNA, such as when the mRNA or a mixture of mRNAs is encapsulated inside a lipid nanoparticle.
BOPI
Sede Electrónica
